Skip to main content
. 2024 Dec 15;14(12):5752–5768. doi: 10.62347/QCDR9612

Figure 3.

Figure 3

The combination of DX126-262 and Cisplatin or 5-FU showed a significant synergistic effect in Her2-positive gastric cancer cells in vitro. (A, D) In vitro cell growth inhibitory activities for combination treatment of DX126-262 and Cisplatin (A) or 5-FU (D) against NCI-N87 cells were evaluated after 5 days using CCK-8. ns: no significance, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, combination versus single drug. (B, E) Dose-response matrix (inhibition) for DX126-262 and Cisplatin (B) or 5-FU (E) was analyzed by SynergyFinder plus. The inhibition ratio is positively correlated to the degree of redness. (C, F) The synergy landscape over the dose-response matrix of DX126-262 and Cisplatin (C) or 5-FU (F) in NCI-N87 cells were analyzed by DrugComb online tool.